The 1997 ANAO audit reveals that the industry was focused on comparator selection, the incorporation of wider qualitative economic benefits in the evaluation process, and the need to reduce submission churn to accelerate new listings. Sound familiar? …
The last audit shows why more process will never lead to faster access
July 26, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
New report shows precision approach extends lives but many still missing out
November 25, 2025 - - Latest News -
AusBiotech appoints Anthea Stephenson to lead national industry growth program
November 25, 2025 - - Australian Biotech -
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 - - Australian Biotech -
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News